Literature DB >> 25921527

Selective role of the catalytic PI3K subunit p110β in impaired higher order cognition in fragile X syndrome.

Christina Gross1, Nisha Raj2, Gemma Molinaro3, Amanda G Allen4, Alonzo J Whyte5, Jay R Gibson3, Kimberly M Huber3, Shannon L Gourley4, Gary J Bassell6.   

Abstract

Distinct isoforms of the PI3K catalytic subunit have specialized functions in the brain, but their role in cognition is unknown. Here, we show that the catalytic subunit p110β plays an important role in prefrontal cortex (PFC)-dependent cognitive defects in mouse models of Fragile X syndrome (FXS), an inherited intellectual disability. FXS is caused by loss of function of the fragile X mental retardation protein (FMRP), which binds and translationally represses mRNAs. PFC-selective knockdown of p110β, an FMRP target that is translationally upregulated in FXS, reverses deficits in higher cognition in Fmr1 knockout mice. Genetic full-body reduction of p110β in Fmr1 knockout mice normalizes excessive PI3K activity, restores stimulus-induced protein synthesis, and corrects increased dendritic spine density and behavior. Notably, adult-onset PFC-selective Fmr1 knockdown mice show impaired cognition, which is rescued by simultaneous p110β knockdown. Our results suggest that FMRP-mediated control of p110β is crucial for neuronal protein synthesis and cognition.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25921527      PMCID: PMC4426038          DOI: 10.1016/j.celrep.2015.03.065

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  30 in total

1.  Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase.

Authors:  Lei Bi; Ichiro Okabe; David J Bernard; Robert L Nussbaum
Journal:  Mamm Genome       Date:  2002-03       Impact factor: 2.957

Review 2.  Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates.

Authors:  Jeffrey W Dalley; Rudolf N Cardinal; Trevor W Robbins
Journal:  Neurosci Biobehav Rev       Date:  2004-11       Impact factor: 8.989

Review 3.  Dendritic protein synthesis, synaptic plasticity, and memory.

Authors:  Michael A Sutton; Erin M Schuman
Journal:  Cell       Date:  2006-10-06       Impact factor: 41.582

4.  Targeting the endocannabinoid system in the treatment of fragile X syndrome.

Authors:  Arnau Busquets-Garcia; Maria Gomis-González; Thomas Guegan; Carmen Agustín-Pavón; Antoni Pastor; Susana Mato; Alberto Pérez-Samartín; Carlos Matute; Rafael de la Torre; Mara Dierssen; Rafael Maldonado; Andrés Ozaita
Journal:  Nat Med       Date:  2013-03-31       Impact factor: 53.440

5.  Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.

Authors:  Q J Yan; M Rammal; M Tranfaglia; R P Bauchwitz
Journal:  Neuropharmacology       Date:  2005-07-27       Impact factor: 5.250

6.  Prevention by cycloheximide of the audiogenic seizures and tryptophan metabolic disturbances of ethanol withdrawal in rats.

Authors:  R Oretti; S Bano; C J Morgan; A A Badawy; A Bonner; P Buckland; P McGuffin
Journal:  Alcohol Alcohol       Date:  1996-05       Impact factor: 2.826

Review 7.  The mGluR theory of fragile X mental retardation.

Authors:  Mark F Bear; Kimberly M Huber; Stephen T Warren
Journal:  Trends Neurosci       Date:  2004-07       Impact factor: 13.837

8.  PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis.

Authors:  Rong Rong; Jee-Yin Ahn; Honglian Huang; Eiichiro Nagata; Daniel Kalman; Judith A Kapp; Jiancheng Tu; Paul F Worley; Solomon H Snyder; Keqiang Ye
Journal:  Nat Neurosci       Date:  2003-10-05       Impact factor: 24.884

9.  Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses.

Authors:  Ivan Jeanne Weiler; Chad C Spangler; Anna Y Klintsova; Aaron W Grossman; Soong Ho Kim; Valerie Bertaina-Anglade; Hooma Khaliq; Froukje E de Vries; Femke A E Lambers; Fatima Hatia; Christine K Base; William T Greenough
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-17       Impact factor: 11.205

10.  Circuit level defects in the developing neocortex of Fragile X mice.

Authors:  J Tiago Gonçalves; James E Anstey; Peyman Golshani; Carlos Portera-Cailliau
Journal:  Nat Neurosci       Date:  2013-06-02       Impact factor: 24.884

View more
  49 in total

Review 1.  Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders.

Authors:  Mustafa Sahin; Mriganka Sur
Journal:  Science       Date:  2015-10-15       Impact factor: 47.728

2.  PI3K isoform-selective inhibition in neuron-specific PTEN-deficient mice rescues molecular defects and reduces epilepsy-associated phenotypes.

Authors:  Angela R White; Durgesh Tiwari; Molly C MacLeod; Steve C Danzer; Christina Gross
Journal:  Neurobiol Dis       Date:  2020-07-24       Impact factor: 5.996

Review 3.  PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling.

Authors:  Anne R Bresnick; Jonathan M Backer
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

4.  Reward-Related Expectations Trigger Dendritic Spine Plasticity in the Mouse Ventrolateral Orbitofrontal Cortex.

Authors:  Alonzo J Whyte; Henry W Kietzman; Andrew M Swanson; Laura M Butkovich; Britton R Barbee; Gary J Bassell; Christina Gross; Shannon L Gourley
Journal:  J Neurosci       Date:  2019-04-02       Impact factor: 6.167

Review 5.  Advancing the understanding of autism disease mechanisms through genetics.

Authors:  Luis de la Torre-Ubieta; Hyejung Won; Jason L Stein; Daniel H Geschwind
Journal:  Nat Med       Date:  2016-04       Impact factor: 53.440

Review 6.  Prefrontal cortical BDNF: A regulatory key in cocaine- and food-reinforced behaviors.

Authors:  Elizabeth G Pitts; Jane R Taylor; Shannon L Gourley
Journal:  Neurobiol Dis       Date:  2016-02-26       Impact factor: 5.996

7.  PI3King the right partner: unique interactions and signaling by p110β.

Authors:  Hashem A Dbouk
Journal:  Postdoc J       Date:  2015-06

Review 8.  Dysregulation and restoration of translational homeostasis in fragile X syndrome.

Authors:  Joel D Richter; Gary J Bassell; Eric Klann
Journal:  Nat Rev Neurosci       Date:  2015-09-09       Impact factor: 34.870

Review 9.  Pharmacotherapy for Fragile X Syndrome: Progress to Date.

Authors:  Matthew H Davenport; Tori L Schaefer; Katherine J Friedmann; Sarah E Fitzpatrick; Craig A Erickson
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

10.  MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome.

Authors:  Yue Li; Michael E Stockton; Ismat Bhuiyan; Brian E Eisinger; Yu Gao; Jessica L Miller; Anita Bhattacharyya; Xinyu Zhao
Journal:  Sci Transl Med       Date:  2016-04-27       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.